Engflag

Vinca Minor

Quick links to important sections

Vinca Minor

Vinca Minor_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vinca Minor

What is Vinca Minor? (Vincamine)

Property Description
Active Ingredient Vincamine (Indole Alkaloid)
Form Oral Tablets/Capsules, Standardized Extracts
Pharmacological Class Cerebrovasodilatory Agent, Cerebral Metabolic Enhancer
General Purpose Support for Circulatory Disorders, Brain Wellness
Origin Natural, Plant-derived (Vinca minor)

The Identity and Natural Origin

The core medicinal substance, Vincamine, is defined chemically as an indole alkaloid primarily extracted from the leaves of the lesser periwinkle (Vinca minor), a natural, plant-derived species. This compound is the most significant monoterpenoid indole alkaloid isolated from the plant material. The composition is centered on the purified Vincamine substance, which is typically formulated into oral tablets or capsules, utilizing solid excipients as a base for administration. This substance is clinically recognized for its effects on vascular tone and regional blood flow, distinguishing it from generic supplements.

Pharmacological Class and General Purpose

Vincamine is pharmacologically classified as a Cerebrovasodilatory Agent and is further recognized as a Cerebral Metabolic Enhancer. This classification indicates the medicine's primary physiological action is to selectively improve regional cerebral blood flow and support the internal energy processes necessary for neuronal homeostasis. The general purpose of this specific pharmacological class is to provide support for brain wellness, and it is typically utilized in scenarios involving circulatory disorders that manifest as reduced cognitive efficiency in adult patients.

Vincamine vs. Analogue Forms (Vinpocetine)

Vincamine is the naturally occurring compound, but it is structurally and functionally related to Vinpocetine (Ethyl-apovincaminate), which is a semisynthetic derivative of the original alkaloid. Both are related Vinca alkaloids that share the general action of influencing cerebral circulation. The original Vincamine compound has a long history of use as a prescription medicine in European markets, a factor that differentiates its market positioning from the often-OTC Vinpocetine derivative.

What side effects are possible with Vinca Minor?

Possible Side Effects and Safety Information: Vincamine

The safety profile for Vincamine, the active alkaloid derived from Vinca minor, is formally structured by government health authorities to communicate documented risks, adverse events, and specific usage restrictions.

Adverse Reaction Scope

Category Documented Adverse Reactions and Safety Notes
Common Side Effects Nausea, Vomiting, Headache, and Dizziness are typically classified as common adverse reactions in regulatory documentation.
System-Organ Classes Adverse events are grouped by the physiological system affected, including Gastrointestinal Disorders, Nervous System Disorders, Vascular Disorders (e.g., Hypotension), and Cardiac Disorders.
Serious Adverse Reactions Regulatory documents explicitly highlight the potential for serious, though rare, cardiac events, specifically Arrhythmias associated with QTc interval prolongation, and severe Hypersensitivity Reactions.

Official Safety Restrictions and Constraints

The medicine is subject to defined constraints based on patient health status, as detailed in regulatory prescribing information:

  • Contraindications: Use is officially restricted or contraindicated in patients with a pre-existing condition of QTc prolongation (congenital or acquired), a history of severe cardiac disease (such as recent myocardial infarction), or severe hepatic impairment.
  • Time-Related Patterns: Certain non-serious effects, such as headache and dizziness, may be more frequently observed during the initial phase of treatment or following dose escalation.
  • Population Notes: Use is generally not recommended for the pediatric population due to a lack of sufficient safety data, and caution is noted for use in patients with any degree of hepatic impairment.

Regulatory Summary

This framework ensures that the full range of officially documented risks, from common discomforts to rare serious cardiac events, is clearly defined within the safety profile. The formal classification by frequency and organ system dictates the regulatory understanding of the medicine’s risk profile, emphasizing absolute constraints for use in patients with defined severe cardiac or liver conditions.

Overdose and Emergency Response

Overdose and when to seek help

Information regarding overdosage with the Vinca minor alkaloid, Vincamine, is strictly derived from official government regulatory documentation across global jurisdictions.

Documented Overdose Profile

The publicly accessible regulatory prescribing information, such as the Summary of Product Characteristics (SmPC), does not explicitly detail a unique set of symptoms, signs, or clinical manifestations that characterize an overdosage of Vincamine. Consequently, specific severe or life-threatening outcomes attributable solely to overdosage, such as severe neurological or cardiovascular complications, are not formally documented in the official regulatory labels. The official documents also do not specify any particular dose levels or routes of exposure associated with confirmed overdosage risk, leaving the clinical profile undefined in public sources.

Emergency Response and Management

The regulatory documentation provides no specific, unique emergency response mandate beyond general safety protocols for medicinal products. Immediate medical attention must be sought for any suspected overdose. In the absence of detailed procedural instructions, management is broadly aligned with the general regulatory principle of providing symptomatic and supportive treatment to stabilize the patient.

Antidote and Monitoring

There is no specific antidote for Vincamine overdosage formally stated in the publicly available regulatory labels. Furthermore, the official documents do not publicly specify mandatory requirements for clinical monitoring, such as continuous hospital observation or specialized surveillance. No specific notes regarding increased risk or severity in vulnerable populations are explicitly documented in regulatory sources.

Therapeutic Uses of Vinca Minor

Quick Facts

  • May be used to assist with: Memory difficulties
  • May be used to assist with: Dizziness (vertigo)
  • May be used to assist with: Head discomfort

Vinca minor, commonly known as lesser periwinkle, contains the alkaloid vincamine. Extracts of this plant have been used traditionally and in some European preparations to assist with memory difficulties and other issues related to cerebral insufficiency, which is a reduced blood flow to the brain. This activity is attributed to vincamine's properties that may promote vasodilation and enhance circulation within the cerebral blood vessels.

Historically, the plant and its preparations have also been applied to manage symptoms of dizziness (vertigo) and certain types of head discomfort. The mechanism of action is thought to involve improving oxygen and glucose utilization in the brain. Vincamine and its derivatives have been the subject of research for their potential effects in people experiencing age-related changes in cerebral function.

Folk medicine has also applied Vinca minor preparations as an astringent to manage conditions involving excessive discharge or bleeding, such as diarrhea, excessive menstrual flow, or minor wounds.

Eligibility and Restrictions for Use

Who Can and Cannot Use Vinca Minor? (Vincamine)

Eligibility to use Vincamine, the active alkaloid derived from Vinca minor, is strictly defined by regulatory guidelines, primarily restricting use based on patient demographics and severe pre-existing health conditions.

Contraindicated Populations (Must Not Use)

Population/Condition Eligibility Status Regulatory Rationale
Pregnant Women Contraindicated Risk of adverse reproductive effects and fetal harm
Lactating Women Contraindicated Lack of established safety data for the nursing infant
Pediatric Population Not Recommended Use is not established due to insufficient safety and efficacy data
Severe Cardiac Conditions Contraindicated Includes severe Ischaemic Heart Disease and Cardiac Arrhythmia
Acute CNS Bleeding Contraindicated Includes acute stages of intracerebral hemorrhage

Permitted Population and Limitations

Allowed Use: The medicine is generally intended for the Adult Population (typically 18 years and older) who are receiving support for circulatory disorders.

Limitations: Contraindications also extend to individuals with known Hypersensitivity to Vincamine. The use of the drug requires careful evaluation against the presence of the listed severe cardiovascular or cerebrovascular comorbidities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding Vincamine (the active component of Vinca minor extract) describes several clinically relevant interaction patterns, primarily involving pharmacodynamic and pharmacokinetic mechanisms.

Pharmacodynamic Interactions

Co-administration with anticoagulant or antiplatelet medicines (such as warfarin or aspirin) may result in an additive anti-clotting effect, which is documented to increase the risk of bruising and bleeding. Similarly, combining Vincamine with antihypertensive agents may reinforce blood pressure-lowering activities, leading to an additive hypotensive effect.

Pharmacokinetic and Substance Interactions

Certain medicines that are potent inhibitors of the CYP3A metabolic pathway may cause a pharmacokinetic interaction. This process can reduce the clearance of the Vinca alkaloid, leading to increased serum concentration and altered exposure. Additionally, caution is advised when co-administering with certain substances that can increase the risk of methemoglobinemia. The official information also advises avoiding alcohol and specific herbal products that possess anti-clotting properties due to potential additive risks.

Interaction-Related Restrictions

Regulatory documentation includes formal restrictions, advising avoidance of use in women who are or may become pregnant. This is based on safety concerns related to potential fetal harm, a restriction frequently noted for related Vinca alkaloids.

Mechanism of Action

How Vinca Minor Works

Modulating the Phosphodiesterase 1 (PDE1) Enzyme System

The primary mechanism of action involves the selective, reversible inhibition of Phosphodiesterase type 1 (PDE1). This enzyme-level interaction blocks the hydrolysis of the intracellular second messenger cGMP (cyclic guanosine monophosphate), leading to elevated cGMP concentrations in target cells, particularly within cerebral vascular smooth muscle and specific neuronal populations.

Targeted Influence on Cerebral Hemodynamics

The increase in cGMP concentration initiates a cascade that causes the relaxation of smooth muscle cells in the brain’s microvessels. This action results in selective cerebral vasodilation, which alters regional perfusion and may influence the local transfer of oxygen and nutrients to brain tissues.

Influence on Neuronal Bioenergetics

In addition to vascular effects, the mechanism influences intracellular pathways that modulate neuronal excitability. This involves an alteration of mitochondrial activity and ion channel function, which may affect the nerve cell’s resting membrane potential and contribute to the modulation of glucose and energy substrate utilization within neural pathways.

Dosage and Administration Information

How Vincamine is Used: Official Administration Guidelines

Vincamine, the active principle from Vinca minor, is primarily administered through the oral route using solid dosage forms such as tablets or capsules, including sustained-release preparations. The administration protocol follows a structured, short-term course as defined in documentation in various global markets, which specifies both the initial and maintenance dosing phases.

Labeled Dosing and Scheduling

Therapy typically begins with a higher starting dose (loading) administered on the first day, such as 400 mg in a single dose. This initial step is followed by a maintenance dose of 200 mg taken once daily. The maintenance dose should not be increased, as additional therapeutic benefit is not anticipated at higher levels. The medicine can generally be taken with or without food, with administration often specified for the evening.

Course Duration and Special Conditions

The total treatment regimen is typically restricted to a defined, short-term course that lasts, on average, for 10 days, with a maximum of 14 days. This duration defines the complete treatment cycle.

Specific dosage schedule adjustments are required for certain patient populations. For instance, patients presenting with severe renal impairment must follow a modified, intermittent dosing pattern after the initial loading dose. This adjusted schedule involves administering the maintenance dose of 200 mg on the third day, and subsequently, the dose is repeated only every 48 hours for the remainder of the fixed course.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vinca Minor

Evidence for use in Chronic Circulatory Issues Affecting the Brain

Research has explored the use of the Vinca alkaloid, Vincamine, in adults studied for conditions linked to reduced cerebral circulation. The available evidence includes older, small-scale clinical trials and basic pharmacological studies. Researchers examined outcomes related to systemic or functional imbalance, specifically looking at physiological measurements such as regional cerebral blood flow and global assessments of patient condition.

Studies report how symptoms evolved in the observed populations, and studies examined short-term changes. Findings describe patterns observed in the studies related to vascular activity. Research reviews often conclude that the certainty remains low due to the age and methodology of the existing research. The evidence is derived from settings with varying symptom burdens, and modern comparative studies in this area are limited.

Evidence for use in Age-Related Memory and Cognitive Concerns

Vincamine was studied for conditions marked by functional limitations, such as age-related memory and mental function disturbances. The research includes small, placebo-controlled trials, often conducted several decades ago, which focused on older adults with mild to moderate cognitive impairment. Researchers monitored changes using standardized global cognitive test scores and clinician ratings of patient status, relevant in trials assessing short-term or episodic symptom patterns.

Research examined patterns measured in scores for attention and concentration during the study period. However, findings were mixed across the collected data. Systematic reviews note that the data are heterogeneous and that the evidence base is not consistently clear.

What Remains Uncertain About the Research for Vinca Minor

Overall, evidence quality varies across studies, and the certainty about the findings remains low. Much of the clinical data was generated before current global regulatory standards for trial design were implemented.

Key uncertainties include the reliance on dated study methodologies and the absence of sufficient data regarding long-term effects. Follow-up durations were limited in most key trials, meaning data for extended periods of observation are scarce. Furthermore, the results apply only to the populations studied, and data for certain groups remain insufficient.

Key Studies & References

  1. Observation on the Therapeutic Effect of Vincamine Sustained-Release Capsules on Vestibular Vertigo

Frequently Asked Questions (FAQ)

Common questions about Vinca Minor (FAQ)

Q: How quickly does Vinca Minor start working?

Studies of the medicine’s concentration in the body indicate that the active ingredient, Vincamine, reaches its highest level in the bloodstream approximately one to two hours after an oral dose is taken. This measurement indicates when the medicine is fully absorbed.

Q: How long do the effects of Vinca Minor last?

Official pharmacokinetic data shows that the medicine is cleared from the body relatively quickly. The elimination half-life is around 1 to 2.5 hours, which means half of the active substance is removed from the bloodstream during that time frame.

Q: Does Vinca Minor cause sleepiness or drowsiness?

Official reports note that effects related to the nervous system, such as dizziness (vertigo) and sleep disturbances like somnolence (drowsiness), have been uncommonly reported for this class of medicine. Official documentation may include a general caution about the potential impact of these side effects on activities like driving and operating machinery.

Q: Is Vinca Minor considered safe for long-term use?

Official administration guidelines restrict the use of this medicine to a defined, short-term course, often for a maximum of 14 days. Furthermore, overviews of the existing research indicate that the available data on the safety profile for use over extended periods of time is scarce.

Q: Can older adults use Vinca Minor?

The medicine is intended for the general adult population. Research evidence supporting its use often involves studies conducted on older adults who are receiving support for conditions related to cerebral circulation.

Q: What is the difference between Vinca Minor and similar medicines I see advertised?

The medicine contains Vincamine, which is the natural compound extracted directly from the Vinca minor plant. You may also see the related compound Vinpocetine advertised; official information notes that Vinpocetine is a chemically modified, semisynthetic derivative of the Vincamine alkaloid.

Q: What are the signs of a serious reaction to Vinca Minor?

Official safety documents describe serious adverse events, including signs of severe hypersensitivity (allergic reaction). These signs can include difficulty breathing, significant rash, or swelling of the face, tongue, or throat.

Q: Can people with kidney problems use Vinca Minor?

Official administration guidelines describe specific, modified dosing schedules for patients who have been diagnosed with severe renal impairment (severe kidney problems). This modification is intended to safely adjust the medicine's exposure in the body.

Q: Can people with liver problems use Vinca Minor?

According to official restrictions, the medicine is formally contraindicated (must not be used) in patients with severe hepatic impairment (severe liver problems). The official product information notes that caution is included for use in patients with any degree of liver impairment.

Q: Is Vinca Minor known to cause stomach upset?

Official safety information includes Nausea, Vomiting, and Gastrointestinal Disorders as documented adverse reactions. These are grouped as common side effects that can affect the digestive system, which patients may describe as stomach upset.

Q: Is it normal to feel a mild headache when starting Vinca Minor?

Headache is classified as a common adverse reaction in the official safety profile. Regulatory documents also note that non-serious effects such as headache are observed more frequently during the initial phase when the body is adjusting to the medication.

Q: How is Vinca Minor different from the Vinca plant?

Vinca Minor is the name of the plant from which the medicine is derived. The medicine itself contains Vincamine, which is the highly purified active substance extracted from the plant's leaves. The product is not the plant material itself but the standardized, isolated alkaloid.

Q: Are there different strengths or forms of Vinca Minor?

The medicine is generally manufactured as oral tablets or capsules, with some preparations formulated to be sustained-release for prolonged absorption. Official guidance defines the labeled starting and maintenance doses that are used in therapy.

Q: Is the effect of Vinca Minor immediate, or does it build up over time?

The official administration guidelines involve starting with a higher initial dose, known as a loading dose, followed by a lower maintenance dose. This structured approach is used in medicines that require time to achieve and sustain the necessary concentration in the body for the intended effect.

Q: Are the side effects of Vinca Minor dose-dependent?

Regulatory safety summaries mention that non-serious side effects may be observed more frequently following dose changes or escalation. Additionally, pre-clinical studies have described the medicine’s cardiovascular effects as being dose-dependent.

Q: Is Vinca Minor a prescription drug or over-the-counter?

In several European markets, the medicine is approved and administered as a prescription drug for circulatory support. However, in jurisdictions like the United States, the active component Vincamine may also be available for purchase as a dietary supplement.

Q: Is Vinca Minor available under a generic name?

The generic name for the medicine’s active ingredient is Vincamine. The generic versions of this medicine, which contain the exact same active substance, are identified by this name.

Q: Why does Vinca Minor have a warning about certain medical conditions?

The official warnings and contraindications are based on the medicine’s known physiological actions, particularly its influence on vascular and cardiac activity. They are included to caution against risks such as the potential for serious QTc interval prolongation (an electrical change in the heart) and dangerous interactions in patients with severe pre-existing heart or liver conditions.

Q: Does Vinca Minor have any warnings related to driving or operating machinery?

Official product information includes a specific section addressing the effects of the medicine on the ability to drive and operate machinery. This warning is included because potential side effects, such as dizziness, vertigo, or sleep disturbances, may impair the safe performance of these activities.

Q: Is there an official patient information leaflet for Vinca Minor?

For any product regulated as a prescription medicine, health authorities globally mandate the provision of an official Patient Information Leaflet (PIL) or similar document. This leaflet is designed to give the patient key usage, safety, and regulatory details.

Q: Why does the packaging of Vinca Minor contain a specific warning?

Regulatory bodies require the packaging of medicines to display warnings that highlight critical safety details. These warnings are included to ensure patients are immediately aware of major restrictions, such as formal contraindications for use in pregnancy or the risk of effects like QTc interval prolongation.

How should Vinca Minor be stored and disposed of?

How to Store and Dispose of Vincamine (Vinca Minor Extract)

The official storage and disposal requirements for pharmaceutical products containing Vincamine are strictly defined by regulatory authorities to maintain quality and safety.

Storage Conditions

Requirement Constraint
Temperature Store below 30^circC (room temperature).
Protection Keep the container tightly closed and protect from moisture.
Packaging Store in the original container to protect from light.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

All unused or expired product and waste material must be disposed of in accordance with local regulatory requirements. Medicines should not be disposed of via household trash or wastewater unless specifically instructed by a local authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Vinca Minor found in:

A-Z Index: